Category Archives: Neurotechnology

A new report published today (Tuesday 1 June) has set out how the UK can support the rapid and safe introduction of fusion energy as the technology develops.

Produced by the Regulatory Horizons Council (RHC), an independent expert committee which identifies regulation required to foster technical innovation, the report makes recommendations on how fusion energy should be regulated in light of its inherently lower risk than nuclear alternatives.

Fusion is the process that powers the sun. A fusion power plant would combine hydrogen atoms to generate energy without giving off the carbon emissions that contribute to climate change. The UK hopes to deliver the worlds first prototype fusion power plant, STEP (Spherical Tokamak for Energy Production), by 2040.

The RHC report states that innovation-friendly regulation will allow the technology to be rolled out quickly and safely, boosting the confidence of both the public and investors.

Science Minister Amanda Solloway said:

Fusion energy has enormous potential, offering an inexhaustible source of zero-carbon energy and helping us to cement the UKs position as a science superpower.

Todays report helps put the foundations in place to deliver the worlds first prototype fusion plant by 2040 and ensures we can capitalise on the exciting innovation taking place right here in the UK.

Focusing on the STEP programme announced in October 2019, the report recommends the Health and Safety Executive (HSE) and the Environment Agency lead on developing current regulations and putting the best framework in place for the technology to flourish.

Due to the lower risk associated with fusion that with nuclear fission, the report recommends that the current regulatory approach, led by HSE and the Environment Agency, is the most appropriate framework and that the more stringent regulations applied to nuclear energy would be disproportionate.

To ensure the target of delivering a fusion plant by 2040 is met, the report also recommends the government consults with business and the public on its plans for fusion energy in summer 2021 and begins a public awareness programme to increase understanding of the topic. Additionally, it advises that a joint guidance document is produced by EA, HSE and the Department for Business, Energy and Industrial Strategy (BEIS) to provide further clarity and ensure confidence in the technology.

Following the publication of the report, the government has today confirmed that it will launch a consultation on fusion energy regulation later this year, allowing industry and the public to have their say. The government has published an interim response to the RHC report and will respond to the report in full in early 2022 after its consultation.

Fusion is currently regulated by the Environment Agency (EA) and the Health and Safety Executive (HSE) in England. Legislation which determines environmental protection regulation for fusion apply in England only and is enforced by EA. Regulators in each of the other nations in the UK have the responsibility for carrying out this same function. Health and Safety regulation, currently enforced by HSE, applies across Great Britain but is devolved in Northern Ireland where the Health and Safety Executive Northern Ireland have responsibility.

The Regulatory Horizons Council (RHC) is an independent committee, sponsored by the Department of Business, Energy and Industrial Strategy (BEIS), that identifies the implications of technological innovation. It provides government with impartial, expert advice on the regulatory reform required to support its rapid and safe introduction of new technologies.

It was set up further to recommendations from the governments white paper on Regulating for the Fourth Industrial Revolution and started the fusion energy regulation report in September 2020, alongside other reports on genetic technologies, medical devices, and remotely piloted aircraft systems. It has recently selected the areas of work it will cover later this year, which are pro-innovation regulatory principles, neurotechnology, AI in healthcare, and hydrogen.

Fusion energy research aims to bring the power source of the stars down to earth to give us low-carbon electricity for millennia to come. When light nuclei fuse to form a heavier nucleus, they release bursts of energy. This is the opposite of nuclear fission the reaction that is used in nuclear power stations today in which energy is released when a nucleus splits apart to form smaller nuclei. For additional detail on fusion energy please consult the UKAEAs Fusion in brief guide.

Read more:

New proposals to support rapid and safe rollout of fusion energy - GOV.UK

What Does Neurotechnology Mean?

Neurotechnology as a new prominent tech term describes any technology that helps us to understand brain function, or enables a direct connection of technology with the human nervous system.

Since the technology world has made rapid advances in both observational technology for the human brain and cognitive modeling technology in artificial intelligence, there's a grey area in terms of what constitutes neurotechnology.

One of the most interesting ways to examine the field of neurotechnology is to ask the question of whether neural networks constitute a neurotechnology or not.

If you go from the literal definition of new technology as technology that brings us new understanding of the actual human brain, it could be suggested that neural networks are slightly different in that they attempt to build a corresponding system based on artificial neurons to help computers think more like humans.

You could also say, though, that since neural networks do illuminate contrasting activity with the human brain, they are a type of newer technology. Likewise, physical systems built with arduinos can be described as neurotechnology in the sense that they may imitate or model human cognitive behavior or the anatomy of the human brain in some way.

In that sense, the field of neural technology is vast and diverse. From digital EEGs to complex simulations of human brain function, neurotechnology has tremendous potential, as in some ways, we are starting to converge the cognitive processes of both humans and machines.

Other types of neurotechnology are directly applied for instance, new research on electrodes that will connect directly to the human brain, to reveal more about its exact functions.

Originally posted here:

What is Neurotechnology? - Definition from Techopedia

Story by Wayne Gillam | UW ECE News

Jessie Owen (right), who has a spinal cord injury, spoke at a recent roundtable about her decision to participate in a research study led by UW ECE senior postdoctoral researcher Dr. Fatma Inanici in the lab of UW ECE associate professor Chet Moritz. This study was funded by the Center for Neurotechnology, which Moritz co-directs and of which Dr. Inanici is a member. Owen described what the experience was like and how neurotechnology has impacted her life. In this photo, Dr. Inanici is applying small patches that will deliver electrical currents on the surface of the skin, over the injured area in Owens neck. This electrical stimulation helps the brain to reestablish connections with nerves in the spinal cord. 2018 photo by Marcus Donner

At the age of 27, Jessie Owen was in a devastating car accident that left her with a severe spinal cord injury. She lost much of the function in her hands, arms and legs, and she was diagnosed with central spinal cord syndrome. Her brains ability to send and receive signals to and from the parts of her body below her neck was severely impaired. She had to take a leave of absence from her job as a teacher, and she has since been dependent on a wheelchair and caregivers for day-to-day living.

In 201819 she participated in a groundbreaking research study led by UW ECE senior postdoctoral researcher Dr. Fatma Inanici in the lab of UW ECE associate professor Chet Moritz. This study was funded by the Center for Neurotechnology, which Moritz co-directs and of which Dr. Inanici is a member. In the study, the research team used a device provided by the Centers industry affiliate Onward to apply noninvasive, electrical stimulation to the site of Owens spinal cord injury. This was aimed at improving her hand and arm function. Owen experienced significant functional gains as a result of participating in the study, which enabled her to live much more independently.

Owen spoke at the Spring 2021 CNT End-user Roundtable, which is a space for CNT students, faculty and staff to learn from people with disabilities and potential end users of neurotechnology. The event was organized by CNT Associate Director of Diversity Scott Bellman and moderated by Moritz. Owen took questions from the audience about her decision to participate in the study, what the experience was like for her and how it has impacted her life.

Below this video, which shows how Owen benefited from participating in the study, are some questions from the Roundtable audience and Owens responses, lightly edited for clarity.

Welcome to the CNT End-user Roundtable, Jessie! We appreciate you taking the time today to be with us.

Thank you! Im happy to be here. So, let me tell you a little bit about how I got to be here. At the very end of December 2012, I was in a car accident going over Highway 2 here in Washington. A tree fell on our car, and I sustained a severe spinal cord injury. I broke my neck at the C3 / C4 level. I went to Harborview Medical Center, and I was at Harborview for three to four months. By the time I left, I still had not gained enough function back to drive a power wheelchair with my hand. I was still driving it with my chin.

And then, I got into a skilled nursing facility because I had some broken bones, and I had some other things that needed to heal. For about two years after that time, I did exercise therapy the best I could. I was able to go from a chin drive to a hand drive on my wheelchair. And I did learn to stand, to get up from chairs and transfer [from one seat to another], but my hand function was still pretty low.

I have central spinal cord syndrome, so my legs tend to work a little bit better than my arms, which was great in some ways but frustrating in others. So, I was living with a friend at the time as I continued exercise therapy. I stayed stagnant in my recovery for about two years. I learned to walk a little bit with crutches, but I was definitely using my power wheelchair all the time because its not like I could open a door, or grab things, or cook or any of those things.

Moritz (left) and Dr. Inanici (center) observe as Jon Schlueter (right), a participant who took part in the same study as Owen, measures grip strength by squeezing the device in his hand. Schlueter has sensors on his arms (black cases) to measure his arm muscle activity during the task. 2019 photo by Marcus Donner

What brought you to the study?

I strongly believe that if we want to see change in the spinal cord community and in science, I need to be an active participant. And so over the years, I participated in some studies whenever they came up. When this one with Chet and Fatma came up, I met with them, and they said I might be a good candidate because I had some function in my hands, even though I didnt have great function.

What did you expect from the study?

Honestly, I didnt expect a lot out of it. We just dont know enough scientifically about how to treat spinal cord injuries, so I thought that it was just going to be a feel good experience for me because I was doing my part to help advance science. It was about two years ago when I participated in this study, and I experienced way more results than I anticipated.

In that time, I was able to go from living with a friend to buying my own house, to living independently, to receiving at least 50% less caregiving. My hand function is still not 100%, its not, but it has improved enough to allow me to do a lot of different things, and it has made a significant impact in my life, and that is why Im here.

Owen practices her fine motor skills by using childrens blocks while UW undergraduate researcher Megan Knoernschild reviews data on the electrical stimulation device provided by Center for Neurotechnology industry affiliate Onward. 2018 photo by Marcus Donner

Could you give us some examples of some things that you couldnt do before the study but that you can do now?

Yeah, you know, there are so many of them. One is that I can cook now. I still dont take anything out of the oven (thats pretty scary), but I can do just about anything on the stovetop. I feel much more comfortable using a knife to cut something because even though my right hand is still pretty ridiculous, its open enough that I can stabilize an onion, while I carefully cut on the other side.

I can tie my shoes. I can walk my dog easier because I can clip the leash on him. I can take pictures on my phone. I can actually open my hand and take pictures on my phone without it being a huge struggle. I started a journal, and now I write in it every day, about three to five sentences. Thats something that I could maybe do before the study, but it was so tedious. It still takes me longer than the average person, but its not so painful that its not enjoyable. I take my time, and I like writing.

Another big one is that Im a teacher, and before the study, I really struggled with figuring out how to teach without being able to write very well or use the technology because my fingers werent working. Now, I can point to things better, I can pick stuff up and write more quickly. I feel more confident as a teacher because I have just that little bit more hand function that allows me to do more.

Do you still receive spinal stimulation? If not, were you able to keep the functional gains you made in the study?

I havent received any additional stimulation in the two years since the study. I would say that about 90% of my functional gains remain. I have a lot more hand function in my left hand. I can still keep my right hand open, and I can carefully grasp something with it. The progress Ive made has sustained. I definitely havent gone down significantly, maybe a tiny bit right after the study ended, but I still have enough function for me to live as independently as possible. Im still receiving 50% less care than I was before. Ive honestly just been a lot happier. Youre happier when you have independence.

When you start out with very little function, even regaining 30% more function at a very low level means a huge deal, so its been really meaningful for me to be able to keep the gains that Ive made.

Owen, Dr. Inanici and Knoernschild discuss research data and electrical stimulation levels for the study. 2018 photo by Marcus Donner

What advice would you give to those considering enrolling in study similar to this one? (Read this UW News article for a more complete description of the study.)

Honestly, I would say to do it. Theres no downside to this. It seems that the side effects are so minimal. I had super success with it, but even if you dont, youre not going to get worse. This is a huge opportunity, and its simple, its easy, and it doesnt take a lot of time to set up.

Do you have any closing thoughts?

Im really honored to be in a room with such hardworking and smart and dedicated individuals who are willing to spend time in their careers to make peoples lives better, and you do. You made a big impact on my life and how I get to live. Im really grateful for the work that you do, and Im happy to help. I really hope that this technology expands and becomes available to everyone and that we continue to take this as a stepping-stone and go even further with it.

Learn more about Owens personal experience in the research study in this article. More information about the study is available at UW News, on the Restorative Technologies website and in this associated research paper.

Continue reading here:

The impact of neurotechnology | UW Department of ...

Global Neurotechnology Market: Overview

Neurotechnology is defined as any technological innovation that allows the study or intervention into neurological processes. The nervous system controls every aspect of human biology, and helps it experience every nuance of the environment. Any disruption in this process can be dangerous for an individual. Hence, neurological study and intervention are necessary to alleviate the symptoms of such individuals and to further scientific study into the complex processes of the brain. It encompasses all such infrastructure, whether hardware or software that helps achieve this.

A major use of such technology is aiding treatment of chronic neurological disorders. Also, a recent interest into workings of the brain for enhancement of daily life is noted. This, as per Transparency Market Research, is set to drive the neurotechnology market forward from 2020 to 2030.

Request for Brochure-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78592

Global Neurotechnology Market: Competitive Landscape

The global neurotechnology market is fragmented owing to the presence of a number of innovators and manufactures. These players are merging with various digital platforms and online service providers to increase outreach and capitalize on rising interest in this market.

Some of the notable players are:

Request for Analysis of COVID19 Impact on Neurotechnology Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78592

Global Neurotechnology Market: Key Trends and Drivers

A number of notable factors are lining the landscape of global neurotechnology market over the forecast period. As per Transparency market Research, these are propelling the market upward and forward. From the list of trends and drivers that are positively impacting growth in global neurotechnology market, prominent ones have been identified and some of them have been detailed out below:

Pre book Neurotechnology Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=78592&ltype=S

Global Neurotechnology Market: Regional Analysis

North America and Europe are currently global leaders in the neurotechnology market owing to presence of robust technological infrastructure and world leading research facilities that make use of advanced machines to implement neurological research. As 1 in 4 persons in these regions would be aged 65 or above 65 by 2050 according to the World Health Organization, demand for neurotechnology is expected to steadily increase in these regions.

The Asia Pacific (APAC) region is expected to register the fastest growth in the neurotechnology market in the coming years. As governments in the region give impetus to research and healthcare development, demand for advanced machines to implement these plans will give a boost to this market.

Browse more Market Reports:

Subcutaneous Immunoglobulin Market:

https://www.transparencymarketresearch.com/subcutaneous-immunoglobulin-market.html

Human Microbiome Market:

https://www.transparencymarketresearch.com/human-microbiome-market.html

Foot Orthotic Insoles Market:

https://www.transparencymarketresearch.com/foot-orthotic-insoles-market.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more here:

Neurotechnology Market set to witness surge in demand over the forecast period of 2018-2026 KSU | The Sentinel Newspaper - KSU | The Sentinel...

New technology has enabled a partially paralyzed person to better control a robotic limb by feeding back what the robot can "feel" to the person's brain.

Pittsburgh, Pennsylvania - A huge breakthrough in technology has allowed a partially paralyzed person actually feel what a robotic arm is touching, paving the way for a potential revolution in prosthetics!

The University of Pittsburgh collaborated with Blackrock in what will go down as a significant milestone in neurotechnology.

"It's the first time a BCI for a robotic prosthetic hand has integrated motion commands and touch in real time," according to Wired. BCI stands for brain-computer interface and is essentially the go-between program for paralyzed individuals who are controlling robotic limbs.

Nathan Copeland, the subject in the study who suffers from partial paralysis due to a car accident, was able to double his speed as he used the robotic arm once he was given the artificial tactile (touch) feedback and able to feel what the robot was feeling.

This is an incredible development, as robotic limbs have been controlled through sight up to this point.

Copeland was selected for the test because of his very specific type of injury. He still had some existing nerves, though messages from those nerves couldn't reach his brain correctly. The team mapped what parts of his brain still responded to touch, and recorded what happened in his brain when he imagined different movements.

The team then used Blackrock Neurotech's NeuroPort System and implanted four-micro electrode arrays into Copeland's brain two to read the signals for movement, and two to send signals to his sensory system.

Once Copeland learned how control the robotic limb with just sight feedback, the team switched on the feature that made his brain feel what the robot did, and it changed everything instantly.

One of the study's authors, biomedical engineer Jennifer Collinger, said, "you don't necessarily rely on vision for a lot of the things that you do. When you're interacting with objects, you rely on your sense of touch."

By placing sensors on the fingertips of the robotic arm and hand, as well as torque sensors on the fingers to relay pressure, whatever the robot feels was sent back as electrical impulses to Copeland's brain, allowing him to feel those pressures in his fingers and hands.

"The first time we did it, I was like, magically better somehow," Copeland said of his experience with artificial touch. He could also complete his tasks twice as fast because he didn't have to double-check visually what he could feel.

Having just published their study in Science, the team is still working out kinks in the system, such as making the sensations that Copeland feels a bit more natural. He might feel a poking sensation when it should be more of a rubbing one, for example.

The system is also wired, and requires being plugged into the sensors embedded in his skull. Once a way is made for him to be able to operate the arm outside the lab, then his life could be opened up to countless other tasks.

Copeland's successes are drawing so much attention that he was able to sell a picture of a cat he drew with his robotic arm recently.

View original post here:

Brain chip developed by University of Pittsburgh and Neurotech gives paralyzed man the ability to feel what a robotic arm touches! - TAG24 NEWS

This report studies the Fingerprint Biometrics in the VAR market in many aspects of the industry such as market size, market conditions, market trends and forecasts, and the report also provides brief information on competitors and specific growth opportunities with key market drivers. To provide, find complete Fingerprint Biometrics in the VAR market analysis segmented by company, region, type and application in the report.

The report provides regional analysis and valuable insights into the progress of the Fingerprint Biometrics in the VAR market and approaches related to the Fingerprint Biometrics in the VAR market. The report talks about the dominant aspects of the market and examines each segment.

Top Companies in the Fingerprint Biometrics in the VAR Market- Fulcrum Biometrics, Delaney Secure Ltd., Neurotechnology, 360 Biometrics, AKSA Solution Development, AutoStar Technologies, Bayometric, Bromba Biometrics, California Peripherals and Components, Digital Data Systems, DYDEX-HS, Eyenetwatch and other.

(Exclusive Offer: Flat 25% discount on this report)

Get a Free sample copy of the Fingerprint Biometrics in the VAR market report

https://www.marketinsightsreports.com/reports/10302408993/global-and-china-fingerprint-biometrics-in-the-var-market-size-status-and-forecast-2020-2026/inquiry?mode=126

1.Company Profile

Segment by Type

Non-AFIS Biometrics in VAR

AFIS Biometrics in VAR

Segment by Application

Commercial

Household

Others

Read Full Fingerprint Biometrics in the VAR Market Report (Description, TOC, List of Tables & Figures, and Many More) at:

https://www.marketinsightsreports.com/reports/10302408993/global-and-china-fingerprint-biometrics-in-the-var-market-size-status-and-forecast-2020-2026?mode=126

Geographic Coverage-The report contains detailed country-level analysis, market revenue, market value and forecast analysis of ingestion, revenue and Fingerprint Biometrics in the VAR Market share, growth speed, historical and forecast (2015-2026) of these regions are covered:

-North America (the United States, Canada, and Mexico)

-Europe (Germany, France, UK, Russia, and Italy)

-Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

-South America (Brazil, Argentina, etc.)

-Middle East & Africa (Saudi Arabia, Egypt, Nigeria, and South Africa)

The current market situations and prospects of the sector also have been examined. Additionally, prime strategical activities in the market, which include product developments, mergers, and acquisitions, partnerships, etc., are discussed. Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.)

Major Points Covered in Table of Contents:

Overview of Fingerprint Biometrics in the VAR Market Global Market Status and Forecast by Regions Global Market Status and Forecast by Types Global Market Status and Forecast by Downstream Industry Market Driving Factor Analysis Market Competition Status by Major Manufacturers Major Manufacturers Introduction and Market Data Upstream and Downstream Market Analysis Cost and Gross Margin Analysis Marketing Status Analysis Market Report Conclusion Research Methodology and Reference

Key Questions Answered by Fingerprint Biometrics in the VAR Market Report

We additionally offer customization on reports based on customer necessity:

1- Free Country-level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any 5 key market players.

3- Free 40 analyst hours to cover any other data points.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com| irfan@marketinsightsreports.com

View original post here:

Fingerprint Biometrics in the VAR Market In-depth Profiling of Key Players and Recent Developments and Forecast Period to 2026|Fulcrum Biometrics,...

News Release

Monday, May 3, 2021

NIH BRAIN Initiative-funded study opens the door to correlating deep brain activity and behavior.

Researchers are now able to wirelessly record the directly measured brain activity of patients living with Parkinsons disease and to then use that information to adjust the stimulation delivered by an implanted device. Direct recording of deep and surface brain activity offers a unique look into the underlying causes of many brain disorders; however, technological challenges up to this point have limited direct human brain recordings to relatively short periods of time in controlled clinical settings.

This project, published in the journal Nature Biotechnology, was funded by the National Institutes of Healths Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

This is really the first example of wirelessly recording deep and surface human brain activity for an extended period of time in the participants home environment, said Kari Ashmont, Ph.D., project manager for the NIH BRAIN Initiative. It is also the first demonstration of adaptive deep brain stimulation at home.

Deep brain stimulation (DBS) devices are approved by the U. S. Food and Drug Administration for the management of Parkinsons disease symptoms by implanting a thin wire, or electrode, that sends electrical signals into the brain. In 2018, the laboratory of Philip Starr, M.D., Ph.D. at the University of California, San Francisco, developed an adaptive version of DBS that adapts its stimulation only when needed based on recorded brain activity. In this study, Dr. Starr and his colleagues made several additional improvements to the implanted technology.

This is the first device that allows for continuous and direct wireless recording of the entire brain signal over many hours, said Dr. Starr. That means we are able to perform whole brain recording over a long period of time while people are going about their daily lives.

The implications of this type of recording are significant. The brain activity patterns (neural signatures) normally used to identify problems such as Parkinsons disease symptoms have traditionally been recorded in clinical settings over short periods of time. This new technology makes it possible to validate those signatures during ordinary daily activities.

If you ever hope to use in-hospital recordings to modify a disease state through adaptive stimulation, you must show that they are also valid in the real world, said Dr. Starr.

Another advantage to recording over long periods of time is that distinct changes in brain activity (biomarkers) that could predict movement disorders can now be identified for individual patients. Roee Gilron, Ph.D., a postdoctoral scholar in Dr. Starrs lab and first author of this study, explained that this allows for a level of customized DBS treatment that was impossible to achieve previously.

Because we are able to build a biomarker library for each patient, we can now program each DBS unit according to a patients individual needs, said Dr. Gilron. This includes personalized stimulation programs that adapt as the patients needs change throughout the day.

One important consideration that arises is the ethical implication of (nearly) all-day brain recording. Since its beginning, the NIH BRAIN Initiative has recognized the importance of addressing potential ethical considerations pertaining to the development and use of devices that record or modulate brain activity. For instance, the NIH BRAIN Neuroethics Working Group is a group of experts in neuroethics and neuroscience that serves to provide the NIH BRAIN Initiative with input relating to neuroethicsa field that studies the ethical, legal, and societal implications of neuroscience. Alongside funding for neurotechnology research, the Initiative also funds research on the ethical implications of advancements in neurotechnology.

We have had patients approach us with concerns regarding privacy, said Dr. Starr. Although we are not at the point where we can distinguish specific normal behaviors from brain activity recording, it is an absolutely legitimate concern. We have told patients to feel free to remove their wearable devices and to turn off their brain recordings whenever they engage in activities they would like to keep private.

The patients were also invited to participate in NIH BRAIN Initiative-funded neuroethics projects looking to identify concerns about this new technology (MH114860). In addition, individuals who opted out of the implant project were interviewed about their decision. As recommended by a recent BRAIN 2.0 neuroethics report, this information will be used to develop ethical guidelines and protocols for future projects to achieve a healthy balance between discovery and privacy.

One unforeseen benefit of this study was that, because it required little to no direct contact with clinicians following surgery, it was ideally suited for the social distancing that is crucial during the COVID-19 pandemic. The technologies used for remote patient monitoring and telehealth were originally designed for the convenience of study subjects, but they have broader applications to other research projects that have been stalled due to COVID-19.

The technologies we developed and used to communicate and work remotely with our patients can also allow those who do not live close to a clinic to receive over the air updates for their devices and telehealth visits from their neurologists as they manage increasingly complex DBS devices, said Dr. Gilron.

The importance of studying behavior in a natural environment such as the home as it relates to neural activity was emphasized in a recent BRAIN 2.0 neuroscience report. Dr. Ashmont stressed that this study is a significant step in that direction and is going to help scientists understand not only disorders but also the neural representation of behaviors in general.

This research was funded by a grant from the NIH BRAIN Initiative (NS100544).

The NIH BRAIN Initiativeis managed by 10 institutes whose missions and current research portfolios complement the goals of The BRAIN Initiative: National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and other Communication Disorders, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke.

NINDS(http://www.ninds.nih.gov) is the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Gilron, R. et al., Chronic wireless streaming of invasive neural recordings at home for circuit discovery and adaptive stimulation.Nature BiotechnologyMay 3, 2021. DOI:10.1038/s41587-021-00897-5

###

Originally posted here:

Researchers wirelessly record human brain activity during normal life activities - National Institutes of Health

Vancouver, British Columbia--(Newsfile Corp. - May 3, 2021) - The global Neurostimulation Devices Market will be worth USD 13.70 Billion by 2027, according to a current analysis by Emergen Research. The growth of this market can be attributed to the growing incidence of health disorders due to unhealthy lifestyle habits is expected to drive the growth of the neurostimulation devices market. Recent developments in neurotechnology are resulting in the rapid utilization of neurostimulation therapies in treating patients suffering from neurological disorders. The economic development and increasing Healthcare Budgetary Allocation in developing countries is expected to drive the growth of the neurostimulation devices market.

The high cost of the neurostimulation devices and the presence of alternative therapeutic procedures is most likely to hamper the demand for neurostimulation devices over the forecast period. Adverse effects and risks associated with neurostimulation devices such as allergic reaction or prickling of skin might restrict the utilization of the neurostimulation devices. Moreover, Stringent government regulations on device approval might act as a barrier to the growth of the market.

Claim Your FREE Sample Copy with Table of content @ https://www.emergenresearch.com/request-sample/349

Key Highlights From The Report

Key companies include Boston Scientific Corporation, St. Jude Medical, Medtronic, Neuronetics, Inc., Codman & Shurtleff, Inc., Nevro Corporation, Intrapace, Abbott Laboratories, LivaNova PLC, and Bayer AG, among others.

In September 2019, U.S. Food and Drug Administration (FDA) approved Abbott's Proclaim XR recharge free neurostimulation platform for people living with chronic pain. The approval helped Abbott to secure a higher market share and increase its neurostimulation devices product portfolio.

Deep Brain Stimulators held the second largest market share of 19.8% in 2019. The rising incidence of neurological disorders among the rising global geriatric population is expected to boost the demand for Deep Brain Stimulators.

Urinary and Fecal Incontinence is expected to register steady growth over the forecast period. Increasing utilization of the sacral nerve stimulators for the treatment of Urinary and Fecal Incontinence is expected to drive the growth of the neurostimulation devices market.

North America accounted for the largest market share of the Neurostimulation Devices market in 2019 due to the improved healthcare system and government funding for the research and development of neurostimulation devices.

Check Our Prices @ https://www.emergenresearch.com/select-license/349

Story continues

Emergen Research has segmented the global Neurostimulation Devices Market on the basis of Product, Application, and region:

Product Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/neurostimulation-devices-market

Take a Look at our Related Reports:

Organs-on-Chips Market By Type (Liver-on-Chip, Multiple Organs-on-Chips, Kidney-on-Chip, Heart-on-Chip, Lung-on-Chip, Intestine-on-Chip), By Application (Drug Discovery, Physiological Model Development, Toxicology Research), By End-Use (Pharmaceutical Firms, Research Institutes, Personal Care Industry), and By Region Forecast to 2028

RNA Transcriptomics Market By Product (Reagents, Instruments, Software, Service), By Technology (Microarrays, Polymerase Chain Reaction, RNA Sequencing, RNA Interference), By Application (Clinical Diagnostics, Toxicogenomics, Drug Discovery, Comparative Transcriptomics), By End-Use (Hospitals, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations), and By Region

Slide Stainers Market By Product (Reagents, Consumables & Accessories, Equipment), By Technology (Hematoxylin and Eosin, Immunohistochemistry, In Situ Hybridization, Cytology, Microbiology, Hematology, Special Stains), By End-Use (Hospitals and Diagnostic Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Other), and By Region Forecast to 2028

High-performance Liquid Chromatography (HPLC) Market By Product (Instruments, Accessories, Consumables), By Application (Clinical Research, Forensic, Diagnostics, Other), By End-Use (Pharma and Bio-pharmaceutical Companies, Contract Research Organizations, Academic Institutions and Others), and By Region Forecast to 2028

Flow Imaging Microscopy Market By Sample Type (Large Biomolecule, Small Biomolecules, Liquid & Viscous Samples, Microfibers and Nano fibers, Others), By Sample Dispersion (Wet Dispersion, Dry Dispersion), By End-Use (Biotechnology Companies, Pharmaceutical Companies, Water Testing Laboratories, Food & Beverage Companies, Research & Academia, Metal Manufacturing, Chemical & Petrochemical Industries), and By Region Forecast to 2028

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric LeeCorporate Sales SpecialistEmergen Research | Web: http://www.emergenresearch.comDirect Line: +1 (604) 757-9756E-mail: sales@emergenresearch.comFacebook | LinkedIn | Twitter | Blogs

Read Full Press Release @ https://www.emergenresearch.com/press-release/global-neurostimulation-devices-market

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82677

Read the original:

Neurostimulation Devices Market Worth USD 13.70 Billion by 2027: Rising Geriatric Population, Coupled with Increasing Prevalence of Neurological...

Leerink Partners analyst Richard Newitter maintained a Buy rating on Stryker Corporation (NYSE:) on Wednesday, setting a price target of $290, which is approximately 10.42% above the present share price of $262.63.

Newitter expects Stryker Corporation to post earnings per share (EPS) of $0.80 for the second quarter of 2021.

The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $277.The analysts price targets range from a high of $303 to a low of $248.

In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $3.95 billion and a net profit of $465 million. The company's market cap is $98.83 billion.

According to TipRanks.com, Leerink Partners analyst Richard Newitter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.1% and a 70.43% success rate.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Visit link:

Leerink Partners Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com

Groundbreaking cognitive assessment tool helps improve diagnostic process and outcomes

Add after eleventh paragraph of release: To get in touch with HeadworX visit headworxclinic.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005334/en/

The updated release reads:

HEADWORX CHOOSES VOXNEURO INNOVATION TO ENHANCE PATIENT CARE

Groundbreaking cognitive assessment tool helps improve diagnostic process and outcomes

A leading neurophysiological testing facility has selected VoxNeuros innovative technology to provide its patients with more certainty in the diagnosis and treatment of brain conditions, VoxNeuro announced today.

HeadworX, led by neurologist Dr. Abdel Kaleel, MD, M.Sc in Kitchener-Waterloo, is integrating VoxNeuros groundbreaking Cognitive Health Assessment into its clinical practice.

"Our ability to offer the VoxNeuro Cognitive Health Assessment will be an incredible extension to our clinical exam, allowing us to develop a more realistic and complete picture of the patient's road to recovery," said Dr. Kaleel.

Dr. John F. Connolly, Chief Science Officer and Co-Founder of VoxNeuro, said HeadworX is a much-needed leader in this area.

"Neurology as a profession has been deeply rooted in tradition," he said. "Dr. Kaleel and his colleagues are future-focused and invested in adopting new and innovative technology that can improve his patients medical evaluation and outcomes."

VoxNeuros breakthrough neurotechnology precisely scores cognitive performance by measuring biomarkers in the electrical activity of the brain, much like using a cardiogram to measure the health of the heart. VoxNeuros technology is positioned to globally change the way brain health is managed and treated with their rapid, precise scores of cognitive function including memory, information processing, attention and concentration.

This provides valuable data to the diagnostic process, enabling clinicians to make more accurate diagnoses faster. The data also helps to customize treatments and accurately track how well treatments are working overtime, thus helping to ensure the best possible outcomes for patients.

Story continues

"We welcome the innovation of VoxNeuro because I have long believed that, as a field, we can do a better job of providing patients with the answers they deserve and a clear path to recovery," says Dr. Kaleel. "With the addition of VoxNeuro, our patients can feel very comfortable that we have the most current means of giving them a true understanding of their condition and an ongoing way to ensure their treatment is working."

Backed by more than 30 years of global, peer-reviewed scientific research, VoxNeuros assessment will also help to ease pressure on the healthcare system as a whole.

"With our growing community population, there is a widening gap for neurological services in Canada," says Dr. Kaleel. "Many times, patients are over-treated and over-tested and this can place a substantial burden on our healthcare system and subject the patient to unnecessary harm. With the objective data provided by VoxNeuro, we will be better able to determine if a patients cognitive concerns warrant further investigations or management options."

HeadworX serves patients across southwest Ontario, aged from teens to the elderly. The VoxNeuro assessment will augment the clinics current array of tools which includes Electromyography (EMG), Electro-encephalography (EEG), Transcranial Doppler (TCD) and Ambulatory Blood Pressure Monitor (ABP).

To get in touch with HeadworX visit headworxclinic.com.

About VoxNeuro Give your brain a voice

VoxNeuro is backed by more than 30 years of peer-reviewed scientific research and offers the only neurotechnology that scores multiple cognitive functions to support proactive brain health, informed clinical decision-making and customized care. By analyzing the electrical activity of the brain, VoxNeuro scores its cognitive performance in memory, information processing, attention & concentration.

VoxNeuro is headquartered at McMaster Innovation Park in Hamilton, ON, Canada.

Appointments available at VoxNeuro Test Centers. To learn more, follow VoxNeuro on LinkedIn, Twitter, Instagram, Facebook and YouTube or visit http://www.voxneuro.com.

Ask us about being selected as 1 of 11 emerging growth Canadian Life Sciences Companies by the Government of Canadas Trade Commissioner Service.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005334/en/

Contacts

Media: Connie Burkeinfinitycomm416-809-0766connie@infinitycomm.ca

Excerpt from:

ADDING and REPLACING HeadworX Chooses VoxNeuro Innovation to Enhance Patient Care - Yahoo Finance